ArticleBMC cancer2025
Evaluating IL22RA1 expression as a predictive indicator in human colon cancer progression.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytokine and chemokine networks in colorectal cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundColon cancer is a prevalent malignancy of the digestive tract, consistently ranking among the top three cancers globally in both incidence and mortality. Current standard treatments for colon cancer primarily include surgical resection and adjuvant chemoradiotherapy, while only a limited subset of patients derive substantial benefits from immunotherapy. Consequently, further investigations into the pathogenesis and immune microenvironment of colon cancer, along with the identification of effective therapeutic targets, are crucial for improving patient prognoses.
methodsIn this study, we utilized a multi-color immunohistochemistry (mIHC) assay to examine the expression patterns of IL22RA1, IL22, CD155, and IL22BP in a tissue microarray (TMA) comprising 90 colon cancer samples. Additionally, we assessed the immunolocalization, clinical relevance, and prognostic significance of these molecules.
resultsThe mIHC results, supported by multispectral tissue imaging, revealed that IL22RA1 was predominantly expressed in tumor epithelial cells. Expression levels of IL22RA1, CD155, and IL22BP in colon cancer tissues were markedly higher than those in adjacent normal tissues, with statistically significant differences (t = 6.05, 9.53, 3.91, all P < 0.001). Analysis of TMA and publicly available databases demonstrated that patients with low IL22RA1 expression exhibited significantly improved overall survival (OS) compared to those with high IL22RA1 expression. Furthermore, patients characterized by high co-expression of IL22RA1 and IL22 (IL22RA1
conclusionsElevated IL22RA1 expression in colon cancer tissues was associated with worse patient outcomes, potentially driven by its interaction with IL22 and CD155 in tumorigenesis. These findings underscored the pivotal role of IL22RA1 as a prognostic biomarker and highlighted its potential as a promising immunotherapeutic target for colon cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.